【佳学基因检测】抗血小板治疗增加分泌型 SERPINE1 表达，诱导 MMP1 表达和增加结肠癌转移

基因检测多少钱一次—共识

参加学术会议时获悉《Int J Mol Sci》在. 2022 Aug 24;23(17):9596.发表了一篇题目为《抗血小板治疗增加分泌型 SERPINE1 表达，诱导 MMP1 表达和增加结肠癌转移》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Won-Tae Kim, Jeong-Yeon Mun, Seung-Woo Baek, Min-Hye Kim, Gi-Eun Yang, Mi-So Jeong, Sun Young Choi, Jin-Yeong Han, Moo Hyun Kim, Sun-Hee Leem等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

MMP1,丝氨酸1,抗血小板药物,癌症转移

肿瘤靶向治疗基因检测临床应用结果

与许多关于抗血小板药物抑制癌症生长和转移的报道相反，在接受长期抗血小板治疗的患者中报告了新的实体瘤。我们研究了这些药物在没有血小板的情况下直接对癌细胞的影响，以模拟长期治疗的效果。当将四种抗血小板药物（阿司匹林、氯吡格雷、普拉格雷和替格瑞洛）用于结肠癌细胞时，癌细胞增殖受到抑制，与之前的研究相似。然而，令人惊讶的是，当用嘌呤能 P2Y12 抑制剂（嘌呤能抗血小板剂）处理细胞时，癌细胞的运动性显着增加。因此，确定了基因表达谱以研究 P2Y12 抑制剂对细胞迁移率的影响，并且 Serpin 家族 1 (SERPINE1) 被确定为与三组细胞迁移和细胞死亡相关的常见基因。抗血小板治疗增加了癌细胞中 SERPINE1 的水平，也促进了 SERPINE1 分泌到培养基中。发现增加的 SERPINE1 可诱导 MMP1，从而增加细胞运动性。此外，使用接受这些抗血小板药物的患者的血清证实了 SERPINE1 的增加。基于这些结果，我们提出SERPINE1可以作为一个新的靶基因，在长期抗血小板治疗的患者中预防癌症的发生和转移。丝氨酸1；抗血小板药物；癌症转移。

肿瘤发生与复发转移国际数据库描述：

Contrary to many reports that antiplatelet agents inhibit cancer growth and metastasis, new solid tumors have been reported in patients receiving long-term antiplatelet therapy. We investigated the effects of these agents directly on cancer cells in the absence of platelets to mimic the effects of long-term therapy. When four antiplatelet agents (aspirin, clopidogrel, prasugrel, and ticagrelor) were administered to colon cancer cells, cancer cell proliferation was inhibited similarly to a previous study. However, surprisingly, when cells were treated with a purinergic P2Y12 inhibitor (purinergic antiplatelet agent), the motility of the cancer cells was significantly increased. Therefore, gene expression profiles were identified to investigate the effect of P2Y12 inhibitors on cell mobility, and Serpin family 1 (SERPINE1) was identified as a common gene associated with cell migration and cell death in three groups. Antiplatelet treatment increased the level of SERPINE1 in cancer cells and also promoted the secretion of SERPINE1 into the medium. Increased SERPINE1 was found to induce MMP1 and, thus, increase cell motility. In addition, an increase in SERPINE1 was confirmed using the serum of patients who received these antiplatelet drugs. With these results, we propose that SERPINE1 could be used as a new target gene to prevent the onset and metastasis of cancer in patients with long-term antiplatelet therapy.Keywords: MMP1; SERPINE1; antiplatelet agents; cancer metastasis.